GB Patent

GB2300807A — Oral dosage forms of omega-3 polyunsaturated acids for the treatment of inflammatory bowel disease

Assigned to Tillotts Pharma AG · Expires 1996-11-20 · 29y expired

What this patent protects

Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases…

USPTO Abstract

Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).

Drugs covered by this patent

Patent Metadata

Patent number
GB2300807A
Jurisdiction
GB
Classification
—
Expires
1996-11-20
Drug substance claim
No
Drug product claim
No
Assignee
Tillotts Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.